Blood concentrations of proapoptotic sFas and antiapoptotic Bcl2 and COVID-19 patient mortality,Expert Review of Molecular Diagnostics

当前位置： X-MOL 学术 › Expert Rev. Mol. Diagn. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Blood concentrations of proapoptotic sFas and antiapoptotic Bcl2 and COVID-19 patient mortality
Expert Review of Molecular Diagnostics ( IF 3.9 ) Pub Date : 2021-06-27 , DOI: 10.1080/14737159.2021.1941880
Leonardo Lorente ₁ , María M Martín ₂ , Agustín F González-Rivero ₃ , Antonia Pérez-Cejas ₄ , Mónica Argueso ₅ , Alina Perez ₆ , Luis Ramos-Gómez ₇ , Jordi Solé-Violán ₈ , José Alberto Marcos Y Ramos ₉ , Nazario Ojeda ₁₀ , Alejandro Jiménez ₁₁

Affiliation

Intensive Care Unit, Hospital Universitario De Canarias. Ofra, Santa Cruz de Tenerife, Spain.
Intensive Care Unit, Hospital Universitario Nuestra Señora De Candelaria, Santa Cruz de Tenerife, Spain.
Laboratory Department. Hospital Universitario De Canarias. Ofra, Santa Cruz de Tenerife, Spain.
Laboratory Department, Hospital Universitario de Canarias. Ofra, Tenerife, Spain.
Intensive Care Unit, Complejo Hospitalario Universitario Insular, Las Palmas de Gran Canaria, Spain.
Internal Intensive Care Unit, Hospital Universitario de Canarias. Ofra, Santa Cruz de Tenerife, Spain.
Intensive Care Unit. Hospital General La Palma, Breña Alta, la Palma, Spain.
Intensive Care Unit, Hospital Universitario, Las Palmas de Gran Canaria, Spain.
Intensive Care Unit, Hospital Doctor José Molina Orosa, Arrecife. Lanzarote, Spain.
Department of Anesthesiology, Hospital Universitario, Las Palmas de Gran Canaria, Spain.
Research Unit, Hospital Universitario de Canarias. Ofra, Santa Cruz de Tenerife, Spain.

ABSTRACT

Background: There are no data on circulating concentrations of sFas (proapoptotic protein of extrinsic pathway) and Bcl2 (antiapoptotic protein of intrinsic pathway) in COVID-19 patients. Thus, our objective study was to determine whether an association exists between serum concentrations of sFas and Bcl2 and COVID-19 patient mortality.

Methods: This observational and prospective study of COVID-19 patients was performed in eight Intensive Care Units (ICU) from Canary Islands (Spain). Serum levels of sFas and Bcl2 at ICU admission were determined. Mortality at 30 days was the end-point study.

Results: Surviving patients (n = 42) compared to non-surviving (n = 11) had lower APACHE-II (p < 0.001), lower SOFA (p = 0.004), lower serum sFas levels (p = 0.001) and higher serum Bcl2 levels (p < 0.001). Logistic regression showed an association between high serum sFas levels and mortality after controlling for APACHE-II (OR = 1.004; 95% CI = 1.101–1.007; p = 0.01) or SOFA (OR = 1.003; 95% CI = 1.101–1.106; p = 0.004), and between low serum Bcl2 levels and mortality after controlling for APACHE-II (OR = 0.927; 95% CI = 0.873–0.984; p = 0.01) or SOFA (OR = 0.949; 95% CI = 0.913–0.987; p = 0.01).

Conclusions: Thus, to the best of our knowledge, this is the first study reporting blood levels of sFas and Bcl2 in COVID-19 patients and its association with mortality.

中文翻译：

促凋亡 sFas 和抗凋亡 Bcl2 的血液浓度以及 COVID-19 患者死亡率

摘要

背景：尚无关于 COVID-19 患者中 sFas（外源性途径促凋亡蛋白）和 Bcl2（内源性途径抗凋亡蛋白）循环浓度的数据。因此，我们的目标研究是确定 sFas 和 Bcl2 的血清浓度与 COVID-19 患者死亡率之间是否存在关联。

方法：这项针对 COVID-19 患者的观察性和前瞻性研究是在加那利群岛（西班牙）的八个重症监护病房 (ICU) 中进行的。测定入住 ICU 时的 sFas 和 Bcl2 血清水平。30 天时的死亡率是研究的终点。

结果：与非存活患者 (n = 11) 相比，存活患者 ( n = 42 ) 的 APACHE-II 较低 ( p < 0.001)、SOFA 较低 ( p = 0.004)、血清 sFas 水平较低 ( p = 0.001) 和血清较高Bcl2 水平 ( p < 0.001)。Logistic 回归显示，控制 APACHE-II（OR = 1.004；95% CI = 1.101–1.007；p = 0.01）或 SOFA（OR = 1.003；95% CI = 1.101–1.106；p = 0.01）后，高血清 sFas 水平与死亡率之间存在关联。p = 0.004），以及控制 APACHE-II（OR = 0.927；95% CI = 0.873–0.984；p = 0.01）或 SOFA（OR = 0.949；95% CI = 0.913–0.987）后低血清 Bcl2 水平与死亡率之间的差异；p = 0.01）。

结论：因此，据我们所知，这是第一项报告 COVID-19 患者血液中 sFas 和 Bcl2 水平及其与死亡率关系的研究。

更新日期：2021-08-12

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11